La vendita allo scoperto per SPX Techs dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di SPX Techs. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

SPX Techs (NYSE:SPXC) Azioni, Report sulle vendite allo scoperto

SPX Techs

SPX Technologies Inc supplies engineered heating, ventilation, and air conditioning, or HVAC, products, as well as detection and measurement technologies and power equipment. The company through two reportable segments. The HVAC segment which generates the majority of the revenue for the company, designs, manufactures, installs, and services cooling products, as well as heating and ventilation products. The detection and measurement technologies segment designs, manufactures, and installs underground pipe and cable locators and inspection equipment, bus-fare collection systems, and others. Geographically, the company generates majority of its revenue in the United States and rest from China, United Kingdom and other regions.

SPX Technologies Inc

UBS US EQUITY DE ETF

SINGAPORE EXCHANGE LTD by Singapore Exchange Ltd.

Singapore Exchange Ltd

SINGAPORE EXCH UNSP/ADR by Singapore Exchange Ltd.

Liberty TripAdvisor Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LTRPA#NASDAQ">LTRPA</a>) reported quarterly earnings of $0.05 per share. This is a 101.64 percent increase over losses of $(3.04) per share from the same period last year. The company reported $532.00 million in sales this quarter. This is a 0.19 percent decrease over sales of $533.00 million the same period last year.

Earnings

News

LTRPA

Liberty TripAdvisor Hldgs Q3 EPS $0.05 Up From $(3.04) YoY, Sales $532.00M Down From $533.00M YoY

Guidance
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">$ in millions</td>
<td colspan="1" rowspan="1">FY 2024</td>
<td colspan="1" rowspan="1">FY 2023</td>
<td colspan="1" rowspan="1">YoY Change</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Revenue1</td>
<td colspan="1" rowspan="1">~$794</td>
<td colspan="1" rowspan="1">$750.3</td>
<td colspan="1" rowspan="1">~6%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted Revenue1</td>
<td colspan="1" rowspan="1">~$794</td>
<td colspan="1" rowspan="1">$760.3</td>
<td colspan="1" rowspan="1">~4%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted EBITDA3</td>
<td colspan="1" rowspan="1">$255 - $260</td>
<td colspan="1" rowspan="1">$217.4</td>
<td colspan="1" rowspan="1">17% - 20%</td>
</tr>
</tbody>
</table>
</figure>
&nbsp;

Guidance

Health Care

General

GDRX

GoodRx Expects 2024 Sales Of Around $794M Vs. $800.798M

Morgan Stanley analyst Joseph Moore initiates coverage on Allegro Microsystems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGM#NASDAQ">ALGM</a>) with a Equal-Weight rating and announces Price Target of $21.

Price Target

Initiation

Analyst Ratings

ALGM

Morgan Stanley Initiates Coverage On Allegro Microsystems with Equal-Weight Rating, Announces Price Target of $21

OppFi (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OPFI#NYSE">OPFI</a>) raises FY2024 Adj EPS guidance from $0.73-0.75 to $0.85-0.87 vs $0.74 analyst estimate. Affirms FY2024 sales outlook from $510.00 million-530.00 million to $510.00 million-530.00 million vs $518.97 million estimate.

OPFI

OppFi Raises FY2024 Adj EPS Guidance from $0.73-0.75 to $0.85-0.87 vs $0.74 Est; Affirms FY2024 Sales Guidance  to $510.00M-530.00M vs $518.97M Est

"We will continue to execute on our business model that is focused on long-term brand-building and leveraging our cash generation. With this proven strategy and strong balance sheet we are well positioned to maximize shareholder value through disciplined capital deployment," Mr. Lombardi concluded.
<figure class="table"> 
<table>
<tbody>
<tr>
<td>Fiscal 2025 Outlook</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>Revenue</td>
<td>$1,125 to $1,140 million</td>
</tr>
<tr>
<td>Organic Revenue Growth</td>
<td>Approximately 1%</td>
</tr>
<tr>
<td>Adjusted Diluted E.P.S.</td>
<td>$4.40 to $4.46</td>
</tr>
<tr>
<td>Free Cash Flow</td>
<td>$240 million or more</td>
</tr>
</tbody>
</table>
</figure>

Prestige Consumer Affirms FY25 GAAP EPS Guidance Of $4.40-$4.46 vs $4.49 Est; Sales Of $1.13B-1.14B vs $1.14B Est

HC Wainwright &amp; Co. analyst Scott Buck reiterates Mogo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOGO#NASDAQ">MOGO</a>) with a Buy and maintains $6 price target.

Reiteration

MOGO

HC Wainwright & Co. Reiterates Buy on Mogo, Maintains $6 Price Target

PG&E Sees FY25 Core EPS Of $1.47 to $1.51 Vs. $1.48 Est.

LFST

LifeStance Sees FY24 Revenue $1.228B-$1.248B Vs $1.225B Estimate; Sees Q4 2024 Revenue $302.5M-$322.5M Vs $310.78M Estimate

Adjusted EBITDA is expected to be in the range of $356 to $368 million.&nbsp;

Edgewell Personal Care Expects FY25 Adjusted EPS Of $3.15 - $3.35, Est $3.22

Guidance
For the fourth quarter and full year 2024, management is anticipating the following:
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">$ in millions</td>
<td colspan="1" rowspan="1">4Q 2024</td>
<td colspan="1" rowspan="1">4Q 2023</td>
<td colspan="1" rowspan="1">YoY Change</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Revenue</td>
<td colspan="1" rowspan="1">~$200</td>
<td colspan="1" rowspan="1">$196.6</td>
<td colspan="1" rowspan="1">~2%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted Revenue</td>
<td colspan="1" rowspan="1">~$200</td>
<td colspan="1" rowspan="1">$196.6</td>
<td colspan="1" rowspan="1">~2%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted EBITDA Margin</td>
<td colspan="1" rowspan="1">~34%</td>
<td colspan="1" rowspan="1">29.1%</td>
<td colspan="1" rowspan="1">~490 bps</td>
</tr>
</tbody>
</table>
</figure>
&nbsp;
"For the fourth quarter of 2024, we are guiding to revenue and Adjusted Revenue of approximately $200 million and Adjusted EBITDA Margin of about 34%," said Karsten Voermann, Chief Financial Officer. "While our full year 2024 revenue and Adjusted Revenue expectations are lower than what we previously indicated, we are confident we can achieve strong Adjusted EBITDA of $255 to $260 million, up over 17% from 2023, and Adjusted EBITDA Margin of over 32%, up more than 340 basis points from 2023."

GoodRx Expects Q4 2024 Sales Of Around $200M Vs. $206.251M

PG&E Sees 2024 Non-GAAP Core EPS Of $1.34 to $1.37 (Vs. $1.33-$1.37 Prior) vs $1.36 Est.

Needham analyst Gil Blum reiterates Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) with a Buy and maintains $205 price target.

SRPT

Needham Reiterates Buy on Sarepta Therapeutics, Maintains $205 Price Target

Edgewell Personal Care Expects FY25 Reported Net Sales To Increase Approximately 1.7% - 3.7%, Organic Net Sales To Increase Approximately 1% - 3%

HC Wainwright &amp; Co. analyst Heiko Ihle maintains McEwen Mining (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MUX#NYSE">MUX</a>) with a Buy and raises the price target from $15 to $19.

HC Wainwright & Co. Maintains Buy on McEwen Mining, Raises Price Target to $19

PG&amp;E (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PCG#NYSE">PCG</a>) reported quarterly earnings of $0.37 per share which beat the analyst consensus estimate of $0.33 by 12.12 percent. The company reported quarterly sales of $5.941 billion which missed the analyst consensus estimate of $6.609 billion by 10.11 percent. This is a 0.90 percent increase over sales of $5.888 billion the same period last year.

Earnings Beats

Earnings Misses

PG&E Q3 2024 Adj. EPS $0.37 Beats $0.33 Estimate, Sales $5.941B Miss $6.609B Estimate

Prestige Consumer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PBH#NYSE">PBH</a>) reported quarterly earnings of $1.09 per share which beat the analyst consensus estimate of $1.08 by 0.93 percent. This is a 1.87 percent increase over earnings of $1.07 per share from the same period last year. The company reported quarterly sales of $283.785 million which beat the analyst consensus estimate of $282.093 million by 0.60 percent. This is a 0.88 percent decrease over sales of $286.316 million the same period last year.

Prestige Consumer Q2 2025 Adj. EPS $1.09 Beats $1.08 Estimate, Sales $283.785M Beat $282.093M Estimate

YETI

YETI Expects FY24 Adjusted Sales To Increase Approx. 9% (Versus Previous Outlook Of 8% - 10%), Adjusted EPS Of Approximately $2.65 Vs. Previous Outlook Of $2.61 - $2.65 (Est $2.64)

GoodRx Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDRX#NASDAQ">GDRX</a>) reported quarterly earnings of $0.08 per share which missed the analyst consensus estimate of $0.09 by 11.11 percent. This is a 33.33 percent increase over earnings of $0.06 per share from the same period last year. The company reported quarterly sales of $195.25 million which missed the analyst consensus estimate of $195.65 million by 0.21 percent. This is a 2.79 percent increase over sales of $189.96 million the same period last year.

GoodRx Holdings Q3 2024 Adj EPS $0.08 Misses $0.09 Estimate, Sales $195.25M Miss $195.65M Estimate

Haemonetics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HAE#NYSE">HAE</a>) reported quarterly earnings of $1.12 per share which beat the analyst consensus estimate of $1.07 by 4.67 percent. The company reported quarterly sales of $345.511million &nbsp;which beat the analyst consensus estimate of $342.648 million by 100.00 percent. This is a 100.00 percent decrease over sales of $318.183 million the same period last year.

Haemonetics Q2 2025 Adj. EPS $1.12 Beats $1.07 Estimate, Sales $345.511M Beat $342.648M Estimate

Fourth Quarter
The outlook reflects the impact of closed acquisitions including NEORIS. We have not included the impact of the pending acquisition of First Derivative. EPAM expects the following for the fourth quarter:
<ul>
<li>The Company expects revenues will be in the range of $1.205 billion to $1.215 billion for the fourth quarter reflecting year-over-year growth of 4.6% at the midpoint of the range. Included in the outlook is an inorganic revenue contribution of 5.7% of which 4.7% comes from NEORIS which was acquired on November 1, 2024. The Company expects that revenues on an organic constant currency basis excluding the impact of the exit from Russia will decline 1.5% at the midpoint of the range;</li>
<li>For the fourth quarter, EPAM expects GAAP income from operations to be in the range of 10.5% to 11.5% of revenues and non-GAAP income from operations to be in the range of 16.0% to 17.0% of revenues. Included in the outlook for both GAAP and non-GAAP is a $9.0 million benefit from the Poland R&amp;D incentive;</li>
<li>The Company expects its GAAP effective tax rate to be approximately 26% and its non-GAAP effective tax rate to be approximately 24%; and</li>
<li>EPAM expects GAAP diluted EPS will be in the range of $1.73 to $1.81 for the quarter, and non-GAAP diluted EPS will be in the range of $2.70 to $2.78 for the quarter. The Company expects weighted average diluted shares outstanding for the quarter to be 57.2 million.</li>
</ul>

EPAM

EPAM Expects Q4 Revenue Of $1.205B-$1.215B Vs $1.150B Est, Adj EPS Of $2.70-$2.78 Vs $2.70 Est

SPX Technologies appoints Carpenter as CHRO

IJT: Beating Peers For 3 Years, But No Long-Term Edge

In a report released today, Sunil Koul from Goldman Sachs maintained a Sell rating on SPX (SPXC – Research Report). The company's shares opened tod...

Goldman Sachs Sticks to Their Sell Rating for SPX (SPXC)

Here are the major earnings after the close today

SPX Technologies Non-GAAP EPS of $1.39 beats by $0.03, revenue of $483.7M misses by $15.87M

Narrows FY24 revenue view to $1.97B-$2B from $1.97B-$2.02B, consensus $2B. Backs FY24 adjusted EBITDA view $410M-$430M. Lowe commented further, "Ou...

SPX Technologies backs FY24 adjusted EPS view $5.45-$5.60, consensus $5.54

Reports Q3 revenue $483.7M, consensus $500.79M. Gene Lowe, president and CEO, remarked, "I am pleased with our Q3 financial results, which include ...

SPX Technologies reports Q3 adjusted EPS $1.39, consensus $1.36

SPX Technologies, Inc (SPXC) Q3 2024 Earnings Call Transcript

SPX Corporation ( ($SPXC) ) has realeased its Q3 earnings. Here is a breakdown of the information SPX Corporation presented to its investors. SPX T...

SPX Technologies Reports Strong Q3 2024 Results

Companies in the Industrial Goods sector have received a lot of coverage today as analysts weigh in on SPX (SPXC – Research Report), Generac Holdin...

Analysts Conflicted on These Industrial Goods Names: SPX (SPXC), Generac Holdings (GNRC) and MasTec (MTZ)

ACGL

ACHC

AEIS

ALGT

ALTR

AMRN

AMSC

AMWL

ATEC

AXAHY

BECN

BKNG

CSWI

GKOS

GNRC

HOOD

HTGC

HUBG

IMAX

INVH

IRTC

ISCG

JAKK

JSML

KLAC

LMND

LPLA

MATX

MSFT

PPSI

RIOT

ROOT

SBUX

SIMO

SLYG

SNBR

SPOK

SPSC

SPXC

SSNLF

STAA

STEM

TDOC

TENB

VIOG

Press Releases

SPX Reports Fourth Quarter and Full-Year 2023 Results

SPX Technologies to Report First Quarter 2024 Financial Results

SPX Technologies Reports First Quarter 2024 Results

Management

SPX Technologies Announces Appointment of Cherée Johnson as Chief Legal Officer

SPX Technologies to Report Second Quarter 2024 Financial Results

SPX Technologies Reports Second Quarter 2024 Results

SPX Technologies Announces Appointment of Jennifer Carpenter as Chief Human Resources Officer

Comments

SPX Techs

Vendite allo scoperto

SPX Techs (NYSE:SPXC) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO